Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Percutaneous coronary intervention" patented technology

Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat narrowing (stenosis) of the coronary arteries of the heart found in coronary artery disease. After accessing the blood stream through the femoral or radial artery, the procedure uses coronary catheterization to visualise the blood vessels on X-ray imaging. After this, an interventional cardiologist can perform a coronary angioplasty, using a balloon catheter in which a deflated balloon is advanced into the obstructed artery and inflated to relieve the narrowing; certain devices such as stents can be deployed to keep the blood vessel open. Various other procedures can also be performed.

Procedure information overlay over angiography data

Example systems and techniques are disclosed that may determine at least one treatment strategy for a lesion. An example system may include memory configured to store clinical guidance and / or informatics for a PCI procedure and processing circuitry communicatively coupled to the memory. The processing circuitry may be configured to determine the plurality of treatment pathways. The processing circuitry may be configured to obtain angiogram imaging data of a coronary vasculature of a patient. The processing circuitry may be configured to determine the clinical guidance and / or informatics based at least in part on the angiogram imaging data. The processing circuitry may be configured to output for display the angiogram imaging data and at least a portion of the clinical guidance and / or informatics, wherein the at least a portion of the clinical guidance and / or informatics is overlaid onto the angiogram imaging data.
Owner:MEDTRONIC VASCULAR INC

Use of biomarker in the preparation of kit used in method for early warning of prognosis risk in patient with acute st-segment elevation myocardial infarction

Disclosed is a method for early warning of a prognosis risk in a patient with acute ST-segment elevation myocardial infarction. The biomarker comprises HBP. The present application can effectively evaluate whether patients with acute ST-segment elevation myocardial infarction will experience poor prognosis within 30 days after PCI by monitoring changes in HBP levels, thereby achieving early identification and timely clinical intervention for high-risk patients, improving the response speed and effect of treatment, reducing the incidence of adverse cardiovascular events, and ultimately improving prognosis of patients.
Owner:JOINSTAR BIOMEDICAL TECH CO LTD